Skip to main content

Anavex Life Sciences Corp.

AVXL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001314052

No open-market purchases or sales by Anavex Life Sciences Corp. insiders were filed in the last 90 days; 180 institutions reported holding it in 13F filings for Q2 2026, worth $95.8M in total; no superinvestor holds it.

Q2 2023 vs. Q1 2023

How the institutions holding Anavex Life Sciences Corp. changed between Q1 2023 and Q2 2023.

All holders in Q2 2023All holders in Q1 2023

13F holders of AVXL: Q1 2023 compared with Q2 2023
MeasureQ1 2023Q2 2023Change
Holders141144+3
Shares27.1M25.3M−1.83M (−6.7%)
Value$232.3M$205.6M−$26.6M (−11.5%)

New holders (17)

Institutions that held Anavex Life Sciences Corp. at the end of Q2 2023 but not at the end of Q1 2023.

Institutions new to AVXL in Q2 2023
InstitutionSharesValue% of portfolio
Qube Research & Technologies Ltd187,954$1.53M0.01%
D. E. Shaw & Co., Inc.45,104$366.7K0.00%
Gsa Capital Partners LLP44,139$359.0K0.04%
Franklin Resources Inc34,701$282.1K0.00%
Janney Montgomery Scott LLC25,681$209.0K0.00%
Occudo Quantitative Strategies LP19,080$155.1K0.02%
Schonfeld Strategic Advisors LLC15,683$127.5K0.00%
Miracle Mile Advisors, LLC15,492$126.0K0.00%
Squarepoint Ops LLC15,193$123.5K0.00%
Lido Advisors, LLC12,100$98.4K0.00%
Allworth Financial LP11,018$89.6K0.00%
Aigen Investment Management, LP10,940$88.9K0.01%
Freestone Capital Holdings, LLC10,000$81.3K0.00%
Fiduciary Alliance LLC9,275$75.4K0.02%
Natixis8,000$65.0K0.00%
Allspring Global Investments Holdings, LLC2,065$16.8K0.00%
Huntington National Bank700$5.69K0.00%

Sold out (14)

Institutions that held Anavex Life Sciences Corp. at the end of Q1 2023 and filed for Q2 2023 without it.